{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T14:02:20Z","timestamp":1765980140394,"version":"3.48.0"},"reference-count":62,"publisher":"Harborside Press, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"\n Background:<\/jats:bold>\n Older adults (OAs) constitute \u226550% of patients with cancer in the United States yet are underrepresented in clinical trials. This study aimed to evaluate the representation of OAs in ECOG-ACRIN (EA) clinical trials and identify factors associated with their participation.\n Patients and Methods:<\/jats:bold>\n OA representation was evaluated in landmark EA trials completed between 2005 and 2019 across breast, gastrointestinal, genitourinary, hematologic, and thoracic malignancies. Enrollment was analyzed by age group and compared with age distributions from population-based SEER registries. Each protocol\u2019s eligibility criteria were reviewed for restrictions, such as any history of atrial fibrillation, New York Heart Association Class I\u2013II heart failure, any cancer within 5 years, serum creatinine level exceeding the institutional upper limit of normal, creatinine clearance (CrCl) <50 mL\/min, abnormal thyroid-stimulating hormone level, or chronic obstructive pulmonary disease on treatment. Chi-square tests were used to compare OA enrollment by race, ECOG performance status (PS), and community versus academic sites.\n Results:<\/jats:bold>\n A total of 15 trials with 26,735 participants were included. The median age at enrollment was 58 years (range, 18\u201392), with 26% of participants aged \u226565 years. Across all tumor types, the median enrollment age was lower than the SEER median age at diagnosis, most notably in genitourinary malignancies (59 vs 73 years). Exclusion criteria were nonrestrictive in only 33% of trials; those with restrictive criteria enrolled participants of lower median age (57 vs 65 years;\n P<\/jats:italic>\n <.001). The proportion of Black\/African American participants declined with increasing age (<65 years: 9.6%; 65\u201375 years: 6.4%; >75 years: 4.8%;\n P<\/jats:italic>\n <.0001). Although older adult enrollment was statistically higher at community compared with academic sites, absolute rates remained low (65\u201375 years: 23.7% vs 20.8%; >75 years: 5.6% vs 4.0%;\n P<\/jats:italic>\n =.036).\n Conclusions:<\/jats:bold>\n OAs, particularly those from racial and ethnic minority groups, remain underrepresented in EA trials across all cancer types, with restrictive eligibility criteria contributing to their underenrollment. Continued efforts are needed to reduce barriers to the enrollment of older adults in clinical trials to ensure representation that reflects the age-related diversity of the cancer population.\n <\/jats:p>","DOI":"10.6004\/jnccn.2025.7076","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:56:19Z","timestamp":1765979779000},"source":"Crossref","is-referenced-by-count":0,"title":["Unveiling Factors Associated With Older Adult Accrual to Cancer Clinical Trials: Lessons From the ECOG-ACRIN Experience"],"prefix":"10.6004","volume":"23","author":[{"given":"Laurie K.","family":"Pearson","sequence":"first","affiliation":[{"name":"University of Massachusetts Chan Medical School, UMass Memorial Medical Center, Worcester, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zheng","sequence":"additional","affiliation":[{"name":"ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita","family":"Nikita","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Jefferson Health, Philadelphia, PA"},{"name":"Department of Medical Oncology, Sidney Kimmel Medical College, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Lu-Yao","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Jefferson Health, Philadelphia, PA"},{"name":"Department of Medical Oncology, Sidney Kimmel Medical College, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn J.","family":"Presley","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne I.","family":"Wagner","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa A.","family":"Simon","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efrat","family":"Dotan","sequence":"additional","affiliation":[{"name":"Penn Medicine, Ann B. Barshinger Cancer Institute, Lancaster, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Int J Cancer","first-page":"49","article-title":"Global cancer incidence in older adults, 2012 and 2035: a population-based study","volume":"144","author":"Pilleron S","year":"2019","unstructured":"Pilleron S, Sarfati D, Janssen-Heijnen M, Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer 2019;144:49\u201358."},{"key":"B2","series-title":"JAMA Netw Open","first-page":"e203842.","article-title":"Association of patient demographic characteristics and insurance status with survival in cancer randomized clinical trials with positive findings","volume":"3","author":"Unger JM","year":"2020","unstructured":"Unger JM, Blanke CD, LeBlanc M, Association of patient demographic characteristics and insurance status with survival in cancer randomized clinical trials with positive findings. JAMA Netw Open 2020;3:e203842."},{"key":"B3","series-title":"N Engl J Med","first-page":"2061","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins LF","year":"1999","unstructured":"Hutchins LF, Unger JM, Crowley JJ, Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061\u20132067."},{"key":"B4","series-title":"J Clin Oncol","first-page":"1383","article-title":"Participation of patients 65 years of age or older in cancer clinical trials","volume":"21","author":"Lewis JH","year":"2003","unstructured":"Lewis JH, Kilgore ML, Goldman DP, Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383\u20131389."},{"key":"B5","series-title":"JAMA","first-page":"2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy VH","year":"2004","unstructured":"Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720\u20132726."},{"key":"B6","series-title":"JAMA Oncol","first-page":"1769","article-title":"Factors associated with age disparities among cancer clinical trial participants","volume":"5","author":"Ludmir EB","year":"2019","unstructured":"Ludmir EB, Mainwaring W, Lin TA, Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol 2019;5:1769\u20131773."},{"key":"B7","series-title":"J Geriatr Oncol","first-page":"1241","article-title":"Disparities in clinical trial participation among older adults with multiple myeloma in the United States","volume":"13","author":"White P","year":"2022","unstructured":"White P, Cooley A, Bal S, Disparities in clinical trial participation among older adults with multiple myeloma in the United States. J Geriatr Oncol 2022;13:1241\u20131243."},{"key":"B8","series-title":"J Geriatr Oncol","first-page":"20","article-title":"Disparities in older adult accrual to cancer trials: analysis from the Alliance for Clinical Trials in Oncology (A151736)","volume":"13","author":"VanderWalde NA","year":"2022","unstructured":"VanderWalde NA, Dockter T, Wakefield DV, Disparities in older adult accrual to cancer trials: analysis from the Alliance for Clinical Trials in Oncology (A151736). J Geriatr Oncol 2022;13:20\u201326."},{"key":"B9","series-title":"J Clin Oncol","first-page":"3457","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria A","year":"2011","unstructured":"Hurria A, Togawa K, Mohile SG, Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29:3457\u20133465."},{"key":"B10","series-title":"Cancer","first-page":"1279","article-title":"Fatigability and endurance performance in cancer survivors: analyses from the Baltimore Longitudinal Study of Aging","volume":"124","author":"Gresham G","year":"2018","unstructured":"Gresham G, Dy SM, Zipunnikov V, Fatigability and endurance performance in cancer survivors: analyses from the Baltimore Longitudinal Study of Aging. Cancer 2018;124:1279\u20131287."},{"key":"B11","series-title":"Cancer","first-page":"3318","article-title":"Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021","volume":"129","author":"Wilson BE","year":"2023","unstructured":"Wilson BE, Desnoyers A, Nadler MB, Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021. Cancer 2023;129:3318\u20133325."},{"key":"B12","series-title":"Acta Oncol","first-page":"249","article-title":"Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis","volume":"59","author":"Ninomiya K","year":"2020","unstructured":"Ninomiya K, Oze I, Kato Y, Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. Acta Oncol 2020;59:249\u2013256."},{"key":"B13","series-title":"J Geriatr Oncol","first-page":"15","article-title":"Current palliative chemotherapy trials in the elderly neglect patient-centred outcome measures","volume":"6","author":"van Bekkum ML","year":"2015","unstructured":"van Bekkum ML, van Munster BC, Thunnissen PLM, Current palliative chemotherapy trials in the elderly neglect patient-centred outcome measures. J Geriatr Oncol 2015;6:15\u201322."},{"key":"B14","series-title":"J Geriatr Oncol","first-page":"101684.","article-title":"Geriatric evaluation methods in oncology and their use in clinical studies: a systematic literature review","volume":"15","author":"Stueger A","year":"2024","unstructured":"Stueger A, Joerger M, De Nys K. Geriatric evaluation methods in oncology and their use in clinical studies: a systematic literature review. J Geriatr Oncol 2024;15:101684."},{"key":"B15","series-title":"J Natl Cancer Inst Monogr","first-page":"107","article-title":"Preface: engaging older adults in cancer clinical trials conducted in the National Cancer Institute Clinical Trials Network: opportunities to enhance accrual","volume":"2022","author":"St Germain D","year":"2022","unstructured":"St Germain D, Mohile SG. Preface: engaging older adults in cancer clinical trials conducted in the National Cancer Institute Clinical Trials Network: opportunities to enhance accrual. J Natl Cancer Inst Monogr 2022;2022:107\u2013110."},{"key":"B16","series-title":"J Natl Cancer Inst Monogr","first-page":"151","article-title":"Infrastructure to support accrual of older adults to National Cancer Institute clinical trials","volume":"2022","author":"Kimmick G","year":"2022","unstructured":"Kimmick G, Sedrak MS, Williams G, Infrastructure to support accrual of older adults to National Cancer Institute clinical trials. J Natl Cancer Inst Monogr 2022;2022:151\u2013158."},{"key":"B17","series-title":"Cancer","first-page":"1630","article-title":"Use of a clinical trial screening tool to enhance patient accrual","volume":"127","author":"St Germain DC","year":"2021","unstructured":"St Germain DC, McCaskill-Stevens W. Use of a clinical trial screening tool to enhance patient accrual. Cancer 2021;127:1630\u20131637."},{"key":"B18","series-title":"J Natl Compr Canc Netw","first-page":"1322","article-title":"Performance status restriction in phase III cancer clinical trials","volume":"18","author":"Abi Jaoude J","year":"2020","unstructured":"Abi Jaoude J, Kouzy R, Mainwaring W, Performance status restriction in phase III cancer clinical trials. J Natl Compr Canc Netw 2020;18:1322\u20131326."},{"key":"B19","series-title":"CA Cancer J Clin","first-page":"78","article-title":"Older adult participation in cancer clinical trials: a systematic review of barriers and interventions","volume":"71","author":"Sedrak MS","year":"2021","unstructured":"Sedrak MS, Freedman RA, Cohen HJ, Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin 2021;71:78\u201392."},{"key":"B20","series-title":"J Natl Cancer Inst Monogr","first-page":"117","article-title":"Enrolling older adults onto National Cancer Institute-funded clinical trials in community oncology clinics: barriers and solutions","volume":"2022","author":"Hopkins JO","year":"2022","unstructured":"Hopkins JO, Braun-Inglis C, Guidice S, Enrolling older adults onto National Cancer Institute-funded clinical trials in community oncology clinics: barriers and solutions. J Natl Cancer Inst Monogr 2022;2022:117\u2013124."},{"key":"B21","series-title":"Oncologist","first-page":"1016","article-title":"Promoting accrual of older patients with cancer to clinical trials: an alliance for clinical trials in oncology member survey (A171602)","volume":"23","author":"Freedman RA","year":"2018","unstructured":"Freedman RA, Dockter TJ, Lafky JM, Promoting accrual of older patients with cancer to clinical trials: an alliance for clinical trials in oncology member survey (A171602). Oncologist 2018;23:1016\u20131023."},{"key":"B22","series-title":"J Clin Oncol","first-page":"3737","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement","volume":"35","author":"Kim ES","year":"2017","unstructured":"Kim ES, Bruinooge SS, Roberts S, Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. J Clin Oncol 2017;35:3737\u20133744."},{"key":"B23","series-title":"J Oncol Pract","first-page":"162","article-title":"Barriers to enrollment of elderly adults in early-phase cancer clinical trials","volume":"4","author":"Basche M","year":"2008","unstructured":"Basche M, Bar\u00f3n AE, Eckhardt SG, Barriers to enrollment of elderly adults in early-phase cancer clinical trials. J Oncol Pract 2008;4:162\u2013168."},{"key":"B24","series-title":"Clin Cancer Res","first-page":"2394","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-Friends of Cancer Research joint research statement","volume":"27","author":"Kim ES","year":"2021","unstructured":"Kim ES, Uldrick TS, Schenkel C, Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-Friends of Cancer Research joint research statement. Clin Cancer Res 2021;27:2394\u20132399."},{"key":"B25","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence \u2013 SEER Research Data, 9 Registries, Nov 2019 Sub (1975\u20132017) \u2013 Linked To County Attributes \u2013 Time Dependent (1990\u20132017) Income\/Rurality, 1969\u20132017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program; released April 2020. Based on the November 2019 submission. Accessed October 1, 2024. Available at: https:\/\/seer.cancer.gov\/seerstat"},{"key":"B26","series-title":"JAMA Oncol","first-page":"1786","article-title":"Clinical trial participation among older adult Medicare Fee-for-Service beneficiaries with cancer","volume":"8","author":"Green AK","year":"2022","unstructured":"Green AK, Tabatabai SM, Aghajanian C, Clinical trial participation among older adult Medicare Fee-for-Service beneficiaries with cancer. JAMA Oncol 2022;8:1786\u20131792."},{"key":"B27","series-title":"J Natl Cancer Inst","first-page":"245","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger JM","year":"2019","unstructured":"Unger JM, Vaidya R, Hershman DL, Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst 2019;111:245\u2013255."},{"key":"B28","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"1249","article-title":"AACR cancer disparities progress report 2022","volume":"31","author":"Williams PA","year":"2022","unstructured":"Williams PA, Zaidi SK, Sengupta R. AACR cancer disparities progress report 2022. Cancer Epidemiol Biomarkers Prev 2022;31:1249\u20131250."},{"key":"B29","series-title":"Blood Cancer J","first-page":"67.","article-title":"Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials","volume":"8","author":"Ailawadhi S","year":"2018","unstructured":"Ailawadhi S, Jacobus S, Sexton R, Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 2018;8:67."},{"key":"B30","series-title":"J Clin Oncol","first-page":"3992","article-title":"Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012","volume":"34","author":"Pang HH","year":"2016","unstructured":"Pang HH, Wang X, Stinchcombe TE, Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012. J Clin Oncol 2016;34:3992\u20133999."},{"key":"B31","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"1374","article-title":"Diversity of enrollment in prostate cancer clinical trials: current status and future directions","volume":"29","author":"Rencsok EM","year":"2020","unstructured":"Rencsok EM, Bazzi LA, McKay RR, Diversity of enrollment in prostate cancer clinical trials: current status and future directions. Cancer Epidemiol Biomarkers Prev 2020;29:1374\u20131380."},{"key":"B1","series-title":"Int J Cancer","first-page":"49","article-title":"Global cancer incidence in older adults, 2012 and 2035: a population-based study","volume":"144","author":"Pilleron S","year":"2019","unstructured":"Pilleron S, Sarfati D, Janssen-Heijnen M, Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer 2019;144:49\u201358."},{"key":"B2","series-title":"JAMA Netw Open","first-page":"e203842.","article-title":"Association of patient demographic characteristics and insurance status with survival in cancer randomized clinical trials with positive findings","volume":"3","author":"Unger JM","year":"2020","unstructured":"Unger JM, Blanke CD, LeBlanc M, Association of patient demographic characteristics and insurance status with survival in cancer randomized clinical trials with positive findings. JAMA Netw Open 2020;3:e203842."},{"key":"B3","series-title":"N Engl J Med","first-page":"2061","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins LF","year":"1999","unstructured":"Hutchins LF, Unger JM, Crowley JJ, Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061\u20132067."},{"key":"B4","series-title":"J Clin Oncol","first-page":"1383","article-title":"Participation of patients 65 years of age or older in cancer clinical trials","volume":"21","author":"Lewis JH","year":"2003","unstructured":"Lewis JH, Kilgore ML, Goldman DP, Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383\u20131389."},{"key":"B5","series-title":"JAMA","first-page":"2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy VH","year":"2004","unstructured":"Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720\u20132726."},{"key":"B6","series-title":"JAMA Oncol","first-page":"1769","article-title":"Factors associated with age disparities among cancer clinical trial participants","volume":"5","author":"Ludmir EB","year":"2019","unstructured":"Ludmir EB, Mainwaring W, Lin TA, Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol 2019;5:1769\u20131773."},{"key":"B7","series-title":"J Geriatr Oncol","first-page":"1241","article-title":"Disparities in clinical trial participation among older adults with multiple myeloma in the United States","volume":"13","author":"White P","year":"2022","unstructured":"White P, Cooley A, Bal S, Disparities in clinical trial participation among older adults with multiple myeloma in the United States. J Geriatr Oncol 2022;13:1241\u20131243."},{"key":"B8","series-title":"J Geriatr Oncol","first-page":"20","article-title":"Disparities in older adult accrual to cancer trials: analysis from the Alliance for Clinical Trials in Oncology (A151736)","volume":"13","author":"VanderWalde NA","year":"2022","unstructured":"VanderWalde NA, Dockter T, Wakefield DV, Disparities in older adult accrual to cancer trials: analysis from the Alliance for Clinical Trials in Oncology (A151736). J Geriatr Oncol 2022;13:20\u201326."},{"key":"B9","series-title":"J Clin Oncol","first-page":"3457","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria A","year":"2011","unstructured":"Hurria A, Togawa K, Mohile SG, Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29:3457\u20133465."},{"key":"B10","series-title":"Cancer","first-page":"1279","article-title":"Fatigability and endurance performance in cancer survivors: analyses from the Baltimore Longitudinal Study of Aging","volume":"124","author":"Gresham G","year":"2018","unstructured":"Gresham G, Dy SM, Zipunnikov V, Fatigability and endurance performance in cancer survivors: analyses from the Baltimore Longitudinal Study of Aging. Cancer 2018;124:1279\u20131287."},{"key":"B11","series-title":"Cancer","first-page":"3318","article-title":"Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021","volume":"129","author":"Wilson BE","year":"2023","unstructured":"Wilson BE, Desnoyers A, Nadler MB, Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021. Cancer 2023;129:3318\u20133325."},{"key":"B12","series-title":"Acta Oncol","first-page":"249","article-title":"Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis","volume":"59","author":"Ninomiya K","year":"2020","unstructured":"Ninomiya K, Oze I, Kato Y, Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. Acta Oncol 2020;59:249\u2013256."},{"key":"B13","series-title":"J Geriatr Oncol","first-page":"15","article-title":"Current palliative chemotherapy trials in the elderly neglect patient-centred outcome measures","volume":"6","author":"van Bekkum ML","year":"2015","unstructured":"van Bekkum ML, van Munster BC, Thunnissen PLM, Current palliative chemotherapy trials in the elderly neglect patient-centred outcome measures. J Geriatr Oncol 2015;6:15\u201322."},{"key":"B14","series-title":"J Geriatr Oncol","first-page":"101684.","article-title":"Geriatric evaluation methods in oncology and their use in clinical studies: a systematic literature review","volume":"15","author":"Stueger A","year":"2024","unstructured":"Stueger A, Joerger M, De Nys K. Geriatric evaluation methods in oncology and their use in clinical studies: a systematic literature review. J Geriatr Oncol 2024;15:101684."},{"key":"B15","series-title":"J Natl Cancer Inst Monogr","first-page":"107","article-title":"Preface: engaging older adults in cancer clinical trials conducted in the National Cancer Institute Clinical Trials Network: opportunities to enhance accrual","volume":"2022","author":"St Germain D","year":"2022","unstructured":"St Germain D, Mohile SG. Preface: engaging older adults in cancer clinical trials conducted in the National Cancer Institute Clinical Trials Network: opportunities to enhance accrual. J Natl Cancer Inst Monogr 2022;2022:107\u2013110."},{"key":"B16","series-title":"J Natl Cancer Inst Monogr","first-page":"151","article-title":"Infrastructure to support accrual of older adults to National Cancer Institute clinical trials","volume":"2022","author":"Kimmick G","year":"2022","unstructured":"Kimmick G, Sedrak MS, Williams G, Infrastructure to support accrual of older adults to National Cancer Institute clinical trials. J Natl Cancer Inst Monogr 2022;2022:151\u2013158."},{"key":"B17","series-title":"Cancer","first-page":"1630","article-title":"Use of a clinical trial screening tool to enhance patient accrual","volume":"127","author":"St Germain DC","year":"2021","unstructured":"St Germain DC, McCaskill-Stevens W. Use of a clinical trial screening tool to enhance patient accrual. Cancer 2021;127:1630\u20131637."},{"key":"B18","series-title":"J Natl Compr Canc Netw","first-page":"1322","article-title":"Performance status restriction in phase III cancer clinical trials","volume":"18","author":"Abi Jaoude J","year":"2020","unstructured":"Abi Jaoude J, Kouzy R, Mainwaring W, Performance status restriction in phase III cancer clinical trials. J Natl Compr Canc Netw 2020;18:1322\u20131326."},{"key":"B19","series-title":"CA Cancer J Clin","first-page":"78","article-title":"Older adult participation in cancer clinical trials: a systematic review of barriers and interventions","volume":"71","author":"Sedrak MS","year":"2021","unstructured":"Sedrak MS, Freedman RA, Cohen HJ, Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin 2021;71:78\u201392."},{"key":"B20","series-title":"J Natl Cancer Inst Monogr","first-page":"117","article-title":"Enrolling older adults onto National Cancer Institute-funded clinical trials in community oncology clinics: barriers and solutions","volume":"2022","author":"Hopkins JO","year":"2022","unstructured":"Hopkins JO, Braun-Inglis C, Guidice S, Enrolling older adults onto National Cancer Institute-funded clinical trials in community oncology clinics: barriers and solutions. J Natl Cancer Inst Monogr 2022;2022:117\u2013124."},{"key":"B21","series-title":"Oncologist","first-page":"1016","article-title":"Promoting accrual of older patients with cancer to clinical trials: an alliance for clinical trials in oncology member survey (A171602)","volume":"23","author":"Freedman RA","year":"2018","unstructured":"Freedman RA, Dockter TJ, Lafky JM, Promoting accrual of older patients with cancer to clinical trials: an alliance for clinical trials in oncology member survey (A171602). Oncologist 2018;23:1016\u20131023."},{"key":"B22","series-title":"J Clin Oncol","first-page":"3737","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement","volume":"35","author":"Kim ES","year":"2017","unstructured":"Kim ES, Bruinooge SS, Roberts S, Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. J Clin Oncol 2017;35:3737\u20133744."},{"key":"B23","series-title":"J Oncol Pract","first-page":"162","article-title":"Barriers to enrollment of elderly adults in early-phase cancer clinical trials","volume":"4","author":"Basche M","year":"2008","unstructured":"Basche M, Bar\u00f3n AE, Eckhardt SG, Barriers to enrollment of elderly adults in early-phase cancer clinical trials. J Oncol Pract 2008;4:162\u2013168."},{"key":"B24","series-title":"Clin Cancer Res","first-page":"2394","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-Friends of Cancer Research joint research statement","volume":"27","author":"Kim ES","year":"2021","unstructured":"Kim ES, Uldrick TS, Schenkel C, Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-Friends of Cancer Research joint research statement. Clin Cancer Res 2021;27:2394\u20132399."},{"key":"B25","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence \u2013 SEER Research Data, 9 Registries, Nov 2019 Sub (1975\u20132017) \u2013 Linked To County Attributes \u2013 Time Dependent (1990\u20132017) Income\/Rurality, 1969\u20132017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program; released April 2020. Based on the November 2019 submission. Accessed October 1, 2024. Available at: https:\/\/seer.cancer.gov\/seerstat"},{"key":"B26","series-title":"JAMA Oncol","first-page":"1786","article-title":"Clinical trial participation among older adult Medicare Fee-for-Service beneficiaries with cancer","volume":"8","author":"Green AK","year":"2022","unstructured":"Green AK, Tabatabai SM, Aghajanian C, Clinical trial participation among older adult Medicare Fee-for-Service beneficiaries with cancer. JAMA Oncol 2022;8:1786\u20131792."},{"key":"B27","series-title":"J Natl Cancer Inst","first-page":"245","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger JM","year":"2019","unstructured":"Unger JM, Vaidya R, Hershman DL, Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst 2019;111:245\u2013255."},{"key":"B28","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"1249","article-title":"AACR cancer disparities progress report 2022","volume":"31","author":"Williams PA","year":"2022","unstructured":"Williams PA, Zaidi SK, Sengupta R. AACR cancer disparities progress report 2022. Cancer Epidemiol Biomarkers Prev 2022;31:1249\u20131250."},{"key":"B29","series-title":"Blood Cancer J","first-page":"67.","article-title":"Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials","volume":"8","author":"Ailawadhi S","year":"2018","unstructured":"Ailawadhi S, Jacobus S, Sexton R, Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 2018;8:67."},{"key":"B30","series-title":"J Clin Oncol","first-page":"3992","article-title":"Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012","volume":"34","author":"Pang HH","year":"2016","unstructured":"Pang HH, Wang X, Stinchcombe TE, Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012. J Clin Oncol 2016;34:3992\u20133999."},{"key":"B31","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"1374","article-title":"Diversity of enrollment in prostate cancer clinical trials: current status and future directions","volume":"29","author":"Rencsok EM","year":"2020","unstructured":"Rencsok EM, Bazzi LA, McKay RR, Diversity of enrollment in prostate cancer clinical trials: current status and future directions. Cancer Epidemiol Biomarkers Prev 2020;29:1374\u20131380."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/12\/article-e257076.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/12\/article-e257076.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/12\/article-e257076.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:56:21Z","timestamp":1765979781000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/12\/article-e257076.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":62,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7076","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"type":"print","value":"1540-1405"},{"type":"electronic","value":"1540-1413"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}